Results 221 to 230 of about 1,668,634 (294)

Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD). [PDF]

Med Chem Res
Hu L.
europepmc   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Research advances on the pathogenesis and clinical interventions of post-stroke depression. [PDF]

Front Neurol
Gao L, Song J, Zhao M, Wang R, Chen Y, Li M, An H, Zhou Z, Tan W, Huang Z.   +9 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. [PDF]

Int J Mol Sci
Wirth KJ, Scheibenbogen C.
europepmc   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Pharmacological Incongruity of Lacosamide in the Management of Delirium Complicated by Ileus. [PDF]

Neuropsychopharmacol Rep
Nagamine T.
europepmc   +1 more source

Adiponectin promotes AMPA receptor trafficking and enhances excitatory synaptic transmission at hippocampal synapses via AMP‐activated protein kinase signalling

British Journal of Pharmacology, EarlyView.
Background and Purpose Peripherally derived adiponectin crosses the blood–brain barrier and targets severa0l brain regions. Adiponectin receptors are highly expressed in the hippocampus, and play a pro‐cognitive role as adiponectin markedly influences the functioning of hippocampal synapses.
Alexandra Soca, Patricia Raposo Afonso, Valentin Morfin, James Cantley, Jenni Harvey   +4 more
wiley   +1 more source

The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. [PDF]

Pharmaceuticals (Basel)
Carmellini P, Cuomo A, Rescalli MB, Pinzi M, Dourmas A, Fagiolini A.   +5 more
europepmc   +1 more source

Potentiation effects of the positive allosteric modulator PTC‐174 on NMDA receptors in neonatal male rat substantia nigra dopaminergic neurons

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Positive allosteric modulators bind to secondary binding sites on the receptor and alter receptor conformation and activation, changing agonist potency and efficacy. PTC‐174 is a novel NMDA receptor positive allosteric modulator that particularly enhances activity of receptors containing GluN2C or GluN2D subunits.
Bangyuan Liu, Alasdair J. Gibb
wiley   +1 more source